GlaxoSmithKline PLC Company Profile (NYSE:GSK)

About GlaxoSmithKline PLC (NYSE:GSK)

GlaxoSmithKline PLC logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:GSK
  • CUSIP: N/A
  • Web:
  • Market Cap: $96.50058 billion
  • Outstanding Shares: 2,459,239,000
Average Prices:
  • 50 Day Moving Avg: $41.27
  • 200 Day Moving Avg: $41.84
  • 52 Week Range: $37.20 - $44.58
  • Trailing P/E Ratio: 37.77
  • Foreward P/E Ratio: 13.33
  • P/E Growth: 1.10
Sales & Book Value:
  • Annual Revenue: $39.4 billion
  • Price / Sales: 2.44
  • Book Value: $0.44 per share
  • Price / Book: 88.75
  • Annual Dividend: $1.97
  • Dividend Yield: 5.0%
  • EBIDTA: $10.77 billion
  • Net Margins: 6.48%
  • Return on Equity: 114.93%
  • Return on Assets: 9.25%
  • Debt-to-Equity Ratio: 2.77%
  • Current Ratio: 0.57%
  • Quick Ratio: 0.37%
  • Average Volume: 2.77 million shs.
  • Beta: 1.03
  • Short Ratio: 1.71

Frequently Asked Questions for GlaxoSmithKline PLC (NYSE:GSK)

What is GlaxoSmithKline PLC's stock symbol?

GlaxoSmithKline PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline PLC pay dividends? What is the dividend yield for GlaxoSmithKline PLC?

GlaxoSmithKline PLC announced a quarterly dividend on Wednesday, July 26th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share on Thursday, October 12th. This represents a $1.96 annualized dividend and a yield of 5.03%. The ex-dividend date of this dividend is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC's previous quarterly dividend of $0.46. View GlaxoSmithKline PLC's Dividend History.

How were GlaxoSmithKline PLC's earnings last quarter?

GlaxoSmithKline PLC (NYSE:GSK) issued its earnings results on Wednesday, July, 26th. The company reported $0.70 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. View GlaxoSmithKline PLC's Earnings History.

When will GlaxoSmithKline PLC make its next earnings announcement?

GlaxoSmithKline PLC is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for GlaxoSmithKline PLC.

Where is GlaxoSmithKline PLC's stock going? Where will GlaxoSmithKline PLC's stock price be in 2017?

16 brokers have issued 12 month price objectives for GlaxoSmithKline PLC's shares. Their forecasts range from $37.00 to $50.00. On average, they anticipate GlaxoSmithKline PLC's stock price to reach $43.50 in the next twelve months. View Analyst Ratings for GlaxoSmithKline PLC.

Who are some of GlaxoSmithKline PLC's key competitors?

Who are GlaxoSmithKline PLC's key executives?

GlaxoSmithKline PLC's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer - Designate, Executive Director
  • Simon Dingemans, Chief Financial Officer, Executive Director
  • Patrick Vallance, President - Pharmaceuticals R&D, Executive Director
  • Roger Connor, President - Global Manufacturing & Supply
  • Abbas Hussain, President - Global Pharmaceuticals
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • Luke Miels, President - Global Pharmaceuticals
  • Daniel E Troy, Senior Vice President, General Counsel
  • Claire Thomas, Senior Vice President - Human Resources
  • Nick Hirons, Senior Vice President – Global Ethics and Compliance

Who owns GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (1.02%), Fisher Asset Management LLC (0.51%), State Street Corp (0.42%), Renaissance Technologies LLC (0.38%), Hotchkis & Wiley Capital Management LLC (0.32%) and Bank of New York Mellon Corp (0.24%). View Institutional Ownership Trends for GlaxoSmithKline PLC.

Who sold GlaxoSmithKline PLC stock? Who is selling GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Ameriprise Financial Inc., Miller Howard Investments Inc. NY, Schafer Cullen Capital Management Inc., Equity Investment Corp Acquisition Inc, State Street Corp, JPMorgan Chase & Co. and Eaton Vance Management. View Insider Buying and Selling for GlaxoSmithKline PLC.

Who bought GlaxoSmithKline PLC stock? Who is buying GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Federated Investors Inc. PA, Marshall Wace North America L.P., Fisher Asset Management LLC, Sphera Funds Management LTD., Hotchkis & Wiley Capital Management LLC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for GlaxoSmithKline PLC.

How do I buy GlaxoSmithKline PLC stock?

Shares of GlaxoSmithKline PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline PLC's stock price today?

One share of GlaxoSmithKline PLC stock can currently be purchased for approximately $39.05.

MarketBeat Community Rating for GlaxoSmithKline PLC (NYSE GSK)
Community Ranking:  1.6 out of 5 ()
Outperform Votes:  293 (Vote Outperform)
Underperform Votes:  612 (Vote Underperform)
Total Votes:  905
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $43.50 (11.40% upside)

Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Citigroup Inc.Reiterated RatingNeutralLowView Rating Details
7/24/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold -> BuyLowView Rating Details
4/6/2017BNP ParibasLower Price Target$37.00LowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/9/2017Kepler Capital MarketsInitiated CoverageReduce -> ReduceLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageEqual WeightN/AView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
2/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
12/27/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
10/20/2016InvestecInitiated CoverageBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
9/20/2016Bank of America CorporationReiterated RatingBuy$50.00N/AView Rating Details
9/12/2016HSBC Holdings plcReiterated RatingBuyN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
8/12/2016ArgusBoost Price TargetBuy$48.00 -> $50.00N/AView Rating Details
5/26/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldN/AView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00N/AView Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00N/AView Rating Details
11/6/2015Morgan StanleyReiterated RatingNeutralN/AView Rating Details
10/31/2015Societe GeneraleReiterated RatingSellN/AView Rating Details
10/20/2015Credit Suisse GroupUpgradeUnderperform -> NeutralN/AView Rating Details
(Data available from 8/18/2015 forward)


Earnings History for GlaxoSmithKline PLC (NYSE:GSK)
Earnings by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Earnings History by Quarter for GlaxoSmithKline PLC (NYSE GSK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/20176/30/2017$0.68$0.70$9.52 billion$9.36 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.09 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.21 billion$9.43 billionViewListenView Earnings Details
10/26/2016Q316$0.77$0.83$8.92 billion$9.90 billionViewListenView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53$9.14 billion$9.02 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.55 billion$8.51 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.76 billion$9.12 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.13 billion$9.47 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.36 billion$9.44 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
2017 EPS Consensus Estimate: $2.88
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.59$0.63$0.61
Q2 20171$0.71$0.71$0.71
Q3 20171$0.81$0.81$0.81
Q4 20171$0.75$0.75$0.75
(Data provided by Zacks Investment Research)


Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)
Next Dividend:10/12/2017
Annual Dividend:$1.97
Dividend Yield:5.04%
Dividend Growth:-3.10% (3 Year Average)
Payout Ratio:197.00% (Trailing 12 Months of Earnings)
69.12% (Based on This Year's Estimates)
67.24% (Based on Next Year's Estimates)
Dividend Payments by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Dividend History by Quarter for GlaxoSmithKline PLC (NYSE GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for GlaxoSmithKline PLC (NYSE:GSK)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 8.99%
Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GlaxoSmithKline PLC (NYSE:GSK)
Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
DateHeadline logoShire Gains as it Seeks European Approval For Dry Eye Treatment - - August 15 at 5:42 AM logoShire Gains as it Seeks European Approval For Dry Eye Treatment - August 15 at 5:42 AM logoWhat Happened In Biotech Last Week? - August 14 at 7:37 PM logo[$$] The key to innovation is balancing risk and rigour - August 14 at 7:37 PM logoWhere Does Zika Virus Vaccine Research Stand Now? - August 12 at 6:22 PM logoBiotech movers: Ionis Drops After GSK Bows Out of Partnership - - August 12 at 12:45 AM logoIonis Retains All Rights To Inotersen, IONIS-FB-L Rx; GSK Declines Its Options - August 11 at 7:42 PM logoETFs with exposure to GlaxoSmithKline Plc : August 11, 2017 - August 11 at 7:42 PM logoUK fraud office expects decision on GSK, Rolls-Royce cases next year - August 11 at 1:32 AM logoVEU, TOT, RY, GSK: Large Inflows Detected at ETF - Nasdaq - August 9 at 7:26 PM logoFormer GSK exec resigns from Intellia board due to 'conflict' - August 9 at 7:26 PM logoMexico watchdog finds big pharma faces no competition on some drugs - August 9 at 7:26 PM logo[$$] Blockbuster drugs depend on marketing, not design - August 9 at 7:26 PM logoGlaxoSmithKline PLC (NYSE:GSK) Receives Average Recommendation of "Hold" from Analysts - August 8 at 8:40 PM logoDrugmakers' hopes for gene therapy rise despite tiny sales in Europe - August 8 at 6:58 PM logo[$$] GSK chief says her lack of 'baggage' in pharma is an advantage - August 6 at 5:55 PM logo[$$] GSK chief vows to stop 'drifting off in hobbyland' with R&D - August 6 at 5:55 PM logoAnalysts say a United Therapeutics sale is premature - August 4 at 7:29 PM logoGlaxoSmithKline’s 2Q17 Earnings: Business Segments - August 1 at 7:47 PM logoGSK’s 2Q17 Earnings: Pharmaceuticals Segment - August 1 at 7:47 PM logoHow Gilead Sciences Performed in 2Q17 - August 1 at 7:47 PM logoAugust PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty - August 1 at 7:47 PM logoGlaxoSmithKline’s 2Q17 Earnings: HIV Business - August 1 at 7:47 PM logoJ&J arthritis drug sirukumab raises safety concerns: FDA staff - Reuters - August 1 at 4:54 AM logoFormer Walmart CIO Named Chief Digital And Technology Officer Of GlaxoSmithKline - July 31 at 6:50 PM logo8 Of The Biggest Whistles Ever Blown On Wall Street - July 31 at 6:50 PM logoJ&J arthritis drug sirukumab raises safety concerns -FDA staff - July 31 at 6:50 PM logoGlaxoSmithKline’s 2Q17 Earnings Reveal Growth - July 31 at 6:50 PM logoForeign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings - July 31 at 6:50 PM logoLeerink Swann Research Analysts Cut Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK) - July 31 at 8:31 AM logoGlaxoSmithKline PLC (GSK) Downgraded to "C+" at TheStreet - July 30 at 8:32 PM logoGlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 - July 29 at 11:12 PM logoInteresting GSK Put And Call Options For June 2018 - - Nasdaq - July 28 at 9:54 PM logoGlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance - Nasdaq - July 28 at 9:54 PM logoLeerink Swann Analysts Cut Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK) - July 28 at 7:28 AM logoGlaxoSmithKline PLC (NYSE:GSK) Announces Earnings Results - July 27 at 9:08 PM logoOverhaul Drug R&D? Easier Said Than Done - July 27 at 7:48 PM logoGlaxoSmithKline Capital Inc. -- Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings - July 27 at 7:48 PM logoGlaxoSmithKline PLC's (NYSE:GSK) "Neutral" Rating Reiterated at Citigroup Inc. - July 27 at 2:05 PM logoGlaxoSmithKline PLC (NYSE:GSK) Plans Dividend Increase - $0.49 Per Share - July 27 at 11:17 AM logoDrugmaker GSK calls for at least two years' Brexit transition - July 27 at 5:54 AM logoGlaxo CFO Says Prioritizing R&D for Product Growth - July 27 at 5:54 AM logoGlaxo Looks Beyond the Lab - July 27 at 5:54 AM logoGSK gives up on rare diseases as gene therapy gets two customers - July 27 at 5:54 AM logoGlaxoSmithKline is Now Oversold (GSK) - Nasdaq - July 26 at 7:50 PM logoGlaxo reports 2Q loss - July 26 at 7:50 PM logo[$$] Glaxo Slashes R&D Projects to Focus on Top Prospects - July 26 at 7:50 PM logo$9.52 Billion in Sales Expected for GlaxoSmithKline PLC (GSK) This Quarter - July 26 at 12:01 PM logoAnalysts’ Recommendations for Merck in July 2017 - July 25 at 7:34 PM logoCorporate News Blog - GlaxoSmithKline and Innoviva Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma - July 25 at 7:34 PM



GlaxoSmithKline PLC (GSK) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by Staff